A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA COVID-19 Vaccine and a Recombinant Influenza Vaccine Administered as a Single Injection in Healthy Adults 50 Years of Age or Older
Sponsor: Pfizer
A PHASE2 clinical study on COVID-19 and Influenza, Human, this trial is completed. The trial is conducted by Pfizer and has accumulated 9 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .